Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of Glucose on QTc Interval in Type 1 Diabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01984827
Recruitment Status : Recruiting
First Posted : November 15, 2013
Last Update Posted : September 10, 2019
Sponsor:
Information provided by (Responsible Party):
Richmond Pharmacology Limited

Tracking Information
First Submitted Date  ICMJE November 8, 2013
First Posted Date  ICMJE November 15, 2013
Last Update Posted Date September 10, 2019
Actual Study Start Date  ICMJE February 10, 2019
Estimated Primary Completion Date December 2019   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: March 5, 2019)
ECG Analysis [ Time Frame: 1, 2, 3 Days ]
  • The paired PK and QTc interval parameters pre-dose compared to post-administration of glucose. Clinically significant ECG morphology and interval changes from baseline.
  • The effect on QTc will be calculated using concentration-effect analysis.
Original Primary Outcome Measures  ICMJE
 (submitted: November 14, 2013)
ECG Analysis [ Time Frame: 1, 2, 2.5, 3 and 4 hours ]
The primary analysis will be based on the cross-over design of the study and will use QTcF as heart rate correction (QTcB will be/QTcI may be calculated for reference purposes) and will be based on the change from average baseline. A linear mixed model with sequence, period, sex gender and race, time and time by treatment interaction as fixed effects, and baseline as covariate will be adapted, with subject (nested in sequence) and subject by period interactions as random effects. Two-sided 90 % confidence intervals (CIs) for the difference between each treatment and placebo. All subjects in the safety dataset who have valid ECG data for at least one post-dosing time-point will be included in the primary analysis set.
Change History Complete list of historical versions of study NCT01984827 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: March 8, 2019)
Proportion of Participants with Adverse Events [ Time Frame: 1, 2, 3 Days ]
Haematology, chemistry and urinalysis will be used to assess the proportion of subjects with clinically significant changes in laboratory safety tests. Electrocardiogram (ECG) will be used to assess the proportion of subjects with morphological heart and/or heart rhythm abnormalities. PR, QRS, QT and QTc intervals will be used to assess the proportion of subjects with clinically significant changes in ECG time intervals. Systolic blood pressure, diastolic blood pressure, heart rate, respiratory rate and temperature will be used to assess the proportion of subjects with clinically significant changes in vital signs. All of the above will be used to measure the incidence of adverse events (AEs).
Original Secondary Outcome Measures  ICMJE
 (submitted: November 14, 2013)
  • Pharmacokinetics [ Time Frame: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 5.5 and 6 hours post-dose. ]
    Blood samples for moxifloxacin will be collected at the above times for each period after the corresponding ECG recordings. PK parameters will be analysed descriptively: AUC0-t, Cmax, tmax will be summarised with arithmetic mean, geometric mean, minimum, median, maximum, standard deviation, standard error, CVb(%) and 95% confidence limits of the means for each dose group. Log-transformed AUC0-t, AUC0-∞, Cmax and t½ values will be summarised with geometric mean, standard deviation of the logs, 95% confidence limits and CVb(%).
  • Pharmacodynamic analysis [ Time Frame: 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 5.5 and 6 hours post-dose. ]
    Blood for analysis of glucose and C-peptide will be collected at the above times for each period after the corresponding ECG recordings. Glucose concentrations will be listed for each individual subject by treatment and summarised at each time point by treatment group using the following descriptive statistics: n (the number of subjects), arithmetic mean, SD (standard deviation), geometric mean, CV (coefficient of variation), median, minimum and maximum.
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Effect of Glucose on QTc Interval in Type 1 Diabetes
Official Title  ICMJE A Single Centre, Placebo Controlled, Phase I Study to Evaluate the Effect of Glucose and Moxifloxacin on Cardiac Repolarisation in Male and Female Patients With Type I Diabetes.
Brief Summary High blood glucose levels (hyperglycaemia) and Moxifloxacin (a commonly used antibiotic) have both been shown independently to affect heart activity in healthy volunteers as recorded by ECG. i.e. Both cause prolongation of the QTc interval which is a measure of the time between the start of the Qwave and the end of the Twave during a heartbeat cycle. In this study, the investigators want to find out whether moxifloxacin and hyperglycaemia cause QTc prolongation in Type 1 diabetic patients. The investigators also want to assess whether C-peptide (a fragment if insulin normally found in the blood but not present in the blood of Type 1 diabetics) has the opposite effect on heart activity i.e it shortens the QTc interval will reverse the effect of QTc prolongation in Type 1 diabetes as this may be useful for preventing 'dead in bed' syndrome also known as 'Sudden Cardiac Death' which is more common in diabetic patients compared to healthy volunteers.
Detailed Description

The investigators previous research (Taubel et al., 2013) has shown that in healthy individuals glucose by itself can prolong (with C-peptide antagonising the effects) the QT interval, which has long been used as a clinical index of the duration of ventricular repolarisation. This observation warrants serious attention because it suggests that high glucose levels by themselves may be pro-arrhythmogenic. To investigate whether glucose has an effect on cardiac repolarisation, it would be advantageous to test this in an environment uncomplicated by C-peptide. In order to elucidate the effects of glucose on the QTc in the absence of C-peptide, the investigators will use diabetic patients who are no longer able to release endogenous C-peptide. This will allow better understanding to whether (1) the well established QTc prolongation caused by moxifloxacin is exaggerated by elevated levels of blood glucose, which would be important for evaluating the risk in diabetic patients using an IKr blocking drug such as moxifloxacin, and (2) to investigate whether C-peptide substitution will reverse or attenuate the effect in the presence of moxifloxacin. Using the conditions of a formal TQT study, the investigators would also want to confirm the QTc prolonging effects described in Gordin et al. (2008) and whether in this setting C-Peptide substitution will reverse or attenuate the glucose effect on QTc.

This will be a phase I, single centre, randomised, placebo-controlled, open-label, crossover study designed to evaluate the effect of glucose and C-peptide on cardiac repolarisation using a hyperglycaemic clamp and a single 400 mg dose of moxifloxacin as a positive control in non-elderly male and female patients with type I diabetes. The results from this study will form the basis for decisions for future studies.

This study will be performed in compliance with the protocol, ICH GCP and applicable regulatory requirements including EU GMP requirements for investigational medicinal product(s) (IMPs).

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Condition  ICMJE Diabetes
Intervention  ICMJE
  • Drug: Moxifloxacin
    1. a single oral dose of 400mg Moxifloxacin plus a hyper-glycaemic clamp for 4 hours
    2. a single oral dose of 400mg Moxifloxacin plus C-peptide
    3. a single oral dose of 400mg Moxifloxacin
    4. placebo

    Oral doses of placebo and moxifloxacin will be administered by a Research Physician or Pharmacy staff member between 08:00 a.m. and 10:00 a.m.

    Other Name: Avelox®
  • Other: hyper-glycaemic clamp
    a hyper-glycaemic clamp only for 2 hours followed by a hyper-glycaemic clamp plus C-peptide for 2 hours
    Other Names:
    • glucose infusion
    • glucose clamp
Study Arms  ICMJE
  • Experimental: hyper-glycaemic clamp:
    hyper-glycaemic clamp: intra-venous Glucose as an initial bolus of 250mg/kg followed by a variable maintenance infusion for 4 hours
    Intervention: Other: hyper-glycaemic clamp
  • Experimental: Moxifloxacin
    Single oral dose of 400 mg Moxifloxacin
    Intervention: Drug: Moxifloxacin
  • Placebo Comparator: Placebo
    Placebo
    Intervention: Drug: Moxifloxacin
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: November 14, 2013)
24
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE December 2019
Estimated Primary Completion Date December 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria

A subject will be eligible for inclusion in this study only if all of the following criteria apply:

  1. Subject is a male or female with a confirmed diagnosis of C-peptide deficiency Type 1 diabetes mellitus, HbA1c levels of ≤ 60 mmol/mol and 20 - 64 years of age (inclusive) at screening.
  2. Healthy (apart from the confirmed diagnosis of C-peptide deficiency Type 1 diabetes mellitus) on the physical examination at screening and at admission on Day −1.
  3. Body mass index (BMI) between 18 and 30 kg/m2 (inclusive) at screening and at admission on Day −1, body weight at least 48 kg.
  4. Haematology, biochemistry and urinalysis test results within the normal range to a clinically relevant extent at screening and at admission.
  5. Female subjects who are either:

    1. Non-childbearing potential, e.g. post-menopausal (as defined as amenorrhoea for at least 12 months with no alternative medical cause) or permanently sterile (permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy) OR
    2. Childbearing potential AND (if heterosexually active) agree to use one or more forms of highly effective contraception as defined below, starting at least one menstrual cycle before first study drug administration and continuing until at least 3 months after the end of the systemic exposure of the study drug.

    Highly effective contraceptive methods for females are as follows:

    • Combined (oestrogen- and progestogen-containing) hormonal contraception associated with inhibition of ovulation as follows:
    • Oral
    • Intravaginal
    • Transdermal
    • Progestogen-only hormonal contraception associated with inhibition of ovulation as follows:
    • Oral
    • Injectable
    • Implantable
    • Intrauterine device (IUD)
    • Intrauterine hormone-releasing system (IUS)
    • Bilateral tubal occlusion
    • Male partner vasectomised (with documented evidence of azoospermia)
  6. Male subjects, if heterosexually active and with a female partner of childbearing potential or a pregnant or breastfeeding partner, must agree to use barrier contraception (male condom) for the treatment period and for at least 3 months after study drug administration. Female partners of male subjects who are of childbearing potential must use one or more forms of highly effective contraception as defined above, starting at least one menstrual cycle before (the male subject's) first study drug administration and continuing until at least 3 months after the last dose of the study drug.

    For male subjects who have had a vasectomy (with documented evidence of azoospermia if possible) and agree to use a barrier method (male condom) for the stated time period, no additional contraceptive method is required by their female partner.

  7. Ability to provide written, personally signed, and dated informed consent to participate in the study, in accordance with the ICH Good Clinical Practice (GCP) Guideline E6 (1996) and applicable regulations, before completing any study-related procedures.
  8. Ability to communicate well with the Investigator in the local language, and to understand and comply with the requirements of the study.
  9. Subject has a stable diabetic treatment regimen.

Exclusion Criteria

A subject will not be eligible for inclusion in this study if any of the following criteria apply:

  1. History or clinical evidence of Type 1 diabetes mellitus related secondary complications in particular autonomic neuropathy, rhythm disturbances, post medical history of syncope and potassium abnormalities.
  2. History or clinical evidence of any disease and/or existence of any surgical or medical condition which might interfere with the absorption, distribution, metabolism or excretion of the study drug (appendectomy and herniotomy allowed, cholecystectomy not allowed).
  3. History or clinical evidence of microvascular disease including chronic kidney failure, macular degeneration or any other disease attributed to the microvascular system that in the Investigator's opinion may affect the outcome of the study.
  4. Recent hospitalisation due to hypoglycaemia or hyperglycaemia within the past one month.
  5. History of clinically significant syncope.
  6. Family history of sudden death.
  7. Clinically significant history or family history of congenital long QT syndrome (e.g. Romano-Ward syndrome, Jervell and Lange-Nielson syndrome) or Brugada's syndrome.
  8. History of clinically significant arrhythmias and ischemic heart disease (especially ventricular arrhythmias, atrial fibrillation (AF), recent conversion from AF or coronary spasm).
  9. Conditions predisposing the volunteer to electrolyte imbalances other than Type 1 diabetes (e.g. altered nutritional states, chronic vomiting, anorexia nervosa, bulimia nervosa).
  10. ECG abnormalities in the standard 12-lead ECG (at screening, Day -1 or pre-dose of Day 1) and 24-hour 12 lead Holter ECG or an equivalent assessment and/or submaximal exercise test (at screening) which in the opinion of the Investigator will interfere with the ECG analysis.
  11. Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG that may interfere with the interpretation of QTc interval changes. This includes subjects with any of the following (at screening, Day-1 or pre-dose of Day 1):

    • Sinus node dysfunction.
    • Clinically significant PR (PQ) interval prolongation.
    • Intermittent second or third degree AV block.
    • Incomplete or complete bundle branch block.
    • Sustained cardiac arrhythmia's including (but not limited to) atrial fibrillation or supraventricular tachycardia; any symptomatic arrhythmia with the exception of isolated extra systoles.
    • More than 200 ventricular ectopic beats in 24 hours.
    • Ventricular tachycardia (ventricular tachycardia defined as ≥ 3 successive ventricular ectopic beats at a rate of > 120 bpm).
    • Abnormal T wave morphology.
    • QT interval corrected using the Fridericia's formula (QTcF) > 450 ms. Subject with borderline deviations from these criteria may be included if the deviations do not pose a safety risk, and if agreed between the appointed Cardiologist and the PI.
  12. Has vital signs outside of the following normal range at screening, Day -1 or Day 1 predose:

    1. Blood pressure (BP):

      Supine BP (after at least 5 minutes of supine rest):

      • Systolic blood pressure: 90 - 140 mmHg.
      • Diastolic blood pressure: 40 - 90 mmHg.
    2. Supine pulse rate after at least 5 minutes of rest: 45 - 90 bpm.
  13. Signs and/or symptoms of a clinically relevant acute illness in the four-week period prior to screening.
  14. Veins unsuitable for intravenous puncture or cannulation on either arm (e.g. veins that are difficult to locate, access or puncture, veins with a tendency to rupture during or after puncture).
  15. Known hypersensitivity to any medicines administered in the trial.
  16. Use of prescription medications (other than their usual insulin) within 14 days or 10 half-lives (whichever is longer) prior to Day 1, or any over-the-counter (OTC) medication (including multivitamin, herbal, or homeopathic preparations, excluding hormonal contraception, hormone-replacement therapy, and/or an occasional dose of acetaminophen) within 7 days prior to Day 1 of the dosing period.
  17. Administration of antibiotics 7 days prior to the admission for the study or plan to take antibiotics during the study.
  18. Treatment with an investigational drug within four weeks prior to admission or having participated in more than three investigational drug studies within one year prior to admission.
  19. Positive test results for alcohol or drugs of abuse at screening and on Day −1.
  20. Presence or history of drug or alcohol abuse in the last 5 years, or inability to refrain from alcohol use from 48 hours before screening, dosing and each scheduled visit until the end of the study. Alcohol abuse is defined as regular weekly intake of more than 14 units (for both males and females), using the following NHS alcohol tracker http://www.nhs.uk/Tools/Pages/drinks-tracker.aspx.
  21. Use of tobacco in any form (e.g., smoking or chewing) or other nicotine-containing products in any form (e.g., gum, patch, electronic cigarettes) within 3 months prior to the planned first day of dosing.
  22. Positive test for Hepatitis B surface antigen (HBsAg), Hepatitis C antibody (HCV Ab), or human immunodeficiency virus antibody (HIV Ab) at screening.
  23. Has a legal or mental incapacity or language barriers precluding adequate understanding, co-operation, and compliance with the study requirements at screening.
  24. Any circumstances or conditions, which, in the opinion of the Investigator, may affect full participation in the study or compliance with the protocol.
  25. An inability to follow a standardized diet and meal schedule or inability to fast, as required during the study.
  26. Prior screen failure (where the cause of the screen failure is not deemed to be temporary), participation, or enrolment in this study. Subjects who initially failed due to temporary non-medically significant issues are eligible for re-screening once the cause has resolved.
  27. Objection by the General Practitioner (GP) to the subject entering the study.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 20 Years to 64 Years   (Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Ulrike Lorch, MD FRCA FFPM +44 20 7042 5800 u.lorch@richmondpharmacology.com
Contact: Jorg Taubel, MD FFPM +44 20 7042 5800 j.taubel@richmondpharmacology.com
Listed Location Countries  ICMJE United Kingdom
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01984827
Other Study ID Numbers  ICMJE RPL-01-12
2013-001612-30 ( EudraCT Number )
C12061 ( Other Identifier: Richmond Pharmacology )
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Richmond Pharmacology Limited
Study Sponsor  ICMJE Richmond Pharmacology Limited
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Jorg Taubel, MD FFPM Richmond Pharmacology Limited
PRS Account Richmond Pharmacology Limited
Verification Date September 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP